Overview

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and narcotic pain medications.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, Irvine
Treatments:
Bupivacaine